Fast-tracking new treatment for childhood cancer

May 5, 2014
Fast-tracking new treatment for childhood cancer
An untreated neuroblastoma cell.

(Medical Xpress)—Children fighting a life-threatening form of cancer could be treated with a revolutionary anti-cancer therapy as early as next year, following the formation of a research alliance to fast-track development of a medicine pioneered by Australian researchers.

The Children's Oncology Drug Alliance (CODA) unites the research and resources of UNSW Australia and its commercialisation arm, NewSouth Innovations, research charity The Kids' Cancer Project, ASX-listed Australian biotechnology-company Novogen, and Nationwide Children's Hospital, Columbus, Ohio, to accelerate development of a treatment purpose-built for – the most common form of cancer in infancy.

Currently there is no medicine approved to treat neuroblastoma, a cancer that affects up to 100 children in Australia and around 650 in the United States each year. Childhood cancers – which claim the lives of three Australian children every week – are currently treated with chemotherapies that have been developed for adults with little consideration to the special needs of children.

"For too long, childhood cancers have been neglected despite the progress made with treatments for adult cancers. The Alliance brings together the science, expertise and funding to accelerate the development of a medicine that has the potential to change the way we treat solid cancers in children," said Professor Peter Gunning, Head of the Oncology Research Unit at UNSW Medicine.

The Alliance will progress of a unique form of anti-cancer therapy originally developed by Professor Gunning's UNSW research team and funded by The Kids' Cancer Project. Now being taken forward commercially by Novogen, the drug class known as anti-tropomyosins has been specifically tailored to selectively target the structure of the cancer cell, causing it to collapse without adversely impacting healthy cells.

The Dean of UNSW Medicine Professor Peter Smith, who has worked as a childhood oncologist and is Chair of The Kids' Cancer Project's Research Advisory Committee said: "These drugs are very promising and long overdue. They have the potential to be the most significant development in the treatment of childhood cancer in more than 20 years".

Novogen acquired the anti-tropomyosin technology in 2013 and has used its drug discovery expertise to produce molecules substantially more potent than those originally developed.

Novogen CEO, Dr Graham Kelly, said, "The Holy Grail of childhood cancer therapy is a medicine that is effective against a tumour such as neuroblastoma, but doesn't leave the sort of damage that the child then has to deal with for the rest of their life".

"We believe the anti-tropomyosins we have developed have the potency, selectivity and safety profile to meet the special needs of children," he said.

Novogen is currently finalising pre-clinical research, with the goal of commencing clinical studies in Australia and the United States in 2015. The aim is that the childhood trials will be progressed in parallel with trials of anti-tropomyosins for a number of adult cancers.

Professor Timothy Cripe, Chief of Paediatric Haematology/Oncology/Blood and Marrow Transplantation at the Nationwide Children's Hospital in Columbus, Ohio, affiliated with The Ohio State University, said, "Our research has shown anti-tropomyosins to be highly effective at killing neuroblastoma cells and slowing their growth in animal models".

"The Nationwide Children's Hospital is a major centre in the US for treating children with neuroblastoma. We are eager to test an idea that has been some years in the making," he said.

NewSouth Innovations' COO, Dr Jim Henderson said, "It's important that the cutting-edge research at UNSW is made available in the community. We are enthusiastic that the Alliance will advance UNSW research into an exciting new treatment option for children with cancer". 

The Kids' Cancer Project has supported the anti-tropomyosin research program since its beginnings in 1998, providing funding of $9 million to date. The charity also aims to raise a further $2.7 million to support clinical trials of the new medicine in children with neuroblastoma who have exhausted other treatment options.

Mr Col Reynolds OAM, Founder of The Kids' Cancer Project, said: "Thanks to the generosity of our donors, we have been able to fund the initial research and proof-of-concept studies. The Alliance with Novogen and the other CODA partners now provides the means to progress to the clinical trial phase."

Mr Reynolds said The Kids' Cancer Project would continue to fundraise to ensure that the next phase of research into a treatment for neuroblastoma was not delayed. He highlighted that childhood cancers are second only to breast cancer in terms of the number of years of life lost to cancer in Australia.

"The Alliance would like to see other groups join the cause. We are keen to partner with anyone who can contribute to the development of improved treatment options for children with cancer."

The clinical trials due to start next year are the first important step towards this treatment becoming available to patients on a general basis; the process of which is expected to take a number of years.

Explore further: Chemotherapy hope for hard-to-treat childhood cancers

Related Stories

Chemotherapy hope for hard-to-treat childhood cancers

August 15, 2013
Children with a particularly lethal cancer could benefit from potentially life-saving treatment, following breakthrough work led by researchers at the University of New South Wales (UNSW).

New treatment hope for one of the deadliest childhood cancers

January 30, 2014
Cancer Research UK doctors have launched a new trial which offers a new type of molecular radiotherapy - never before tested in children - for one of the deadliest childhood cancers.

New hope in the fight against childhood cancer

July 11, 2013
Cancer Research UK scientists at the University of Southampton are seeing positive results in a pre-clinical trial that could bring treatments for a particular aggressive form of childhood cancer closer to reality.

Simple blood test could improve treatment for deadly childhood cancer

March 4, 2014
(Medical Xpress)—A simple blood test could pinpoint which children are unlikely to respond to treatment for a particularly aggressive form of neuroblastoma, according to a study published in the Journal of Clinical Oncology ...

Clinical trials to investigate prostate cancer treatment

April 28, 2014
The way prostate cancer is treated could have a radical re-think as two international clinical trials go ahead.

Improved screening means new targets for pediatric neuroblastoma therapies

March 1, 2014
Neuroblastoma is one of the most common and lethal types of childhood cancers. In a paper published online today in OncoTarget, a researcher at the University of Texas Health Science Center at San Antonio unveils the important ...

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.